<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Breast Cancer Res Treat</journal-id><journal-id journal-id-type="iso-abbrev">Breast Cancer Res Treat</journal-id><journal-title-group><journal-title>Breast Cancer Research and Treatment</journal-title></journal-title-group><issn pub-type="ppub">0167-6806</issn><issn pub-type="epub">1573-7217</issn><publisher><publisher-name>Springer US</publisher-name><publisher-loc>New York</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">39427280</article-id><article-id pub-id-type="pmc">PMC11785661</article-id>
<article-id pub-id-type="publisher-id">7506</article-id><article-id pub-id-type="doi">10.1007/s10549-024-07506-4</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Attrition between lines of therapy and real-world outcomes of patients with HER2-positive metastatic breast cancer in Europe: a cohort study leveraging electronic medical records</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Cottu</surname><given-names>Paul</given-names></name><address><email>paul.cottu@curie.fr</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Cheeseman</surname><given-names>Sue</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Hall</surname><given-names>Peter</given-names></name><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>W&#x000f6;ckel</surname><given-names>Achim</given-names></name><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Scholz</surname><given-names>Christian W.</given-names></name><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Bria</surname><given-names>Emilio</given-names></name><xref ref-type="aff" rid="Aff7">7</xref><xref ref-type="aff" rid="Aff8">8</xref></contrib><contrib contrib-type="author"><name><surname>Orlandi</surname><given-names>Armando</given-names></name><xref ref-type="aff" rid="Aff7">7</xref></contrib><contrib contrib-type="author"><name><surname>Ribelles</surname><given-names>Nuria</given-names></name><xref ref-type="aff" rid="Aff9">9</xref></contrib><contrib contrib-type="author"><name><surname>Vallet</surname><given-names>Mah&#x000e9;va</given-names></name><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Niklas</surname><given-names>Nicolas</given-names></name><xref ref-type="aff" rid="Aff10">10</xref></contrib><contrib contrib-type="author"><name><surname>Hogg</surname><given-names>Catherine</given-names></name><xref ref-type="aff" rid="Aff11">11</xref></contrib><contrib contrib-type="author"><name><surname>Aggarwal</surname><given-names>Shivani</given-names></name><xref ref-type="aff" rid="Aff12">12</xref></contrib><contrib contrib-type="author"><name><surname>Moreira</surname><given-names>Joana</given-names></name><xref ref-type="aff" rid="Aff13">13</xref></contrib><contrib contrib-type="author"><name><surname>Lucerna</surname><given-names>Markus</given-names></name><xref ref-type="aff" rid="Aff14">14</xref></contrib><contrib contrib-type="author"><name><surname>Collin</surname><given-names>Simon M.</given-names></name><xref ref-type="aff" rid="Aff15">15</xref></contrib><contrib contrib-type="author"><name><surname>Logue</surname><given-names>Amanda</given-names></name><xref ref-type="aff" rid="Aff16">16</xref></contrib><contrib contrib-type="author"><name><surname>Long</surname><given-names>Gr&#x000e1;inne H.</given-names></name><xref ref-type="aff" rid="Aff15">15</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05f82e368</institution-id><institution-id institution-id-type="GRID">grid.508487.6</institution-id><institution-id institution-id-type="ISNI">0000 0004 7885 7602</institution-id><institution>Department of Medical Oncology, Institut Curie, </institution><institution>Universit&#x000e9; Paris Cit&#x000e9;, </institution></institution-wrap>Paris, France </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00v4dac24</institution-id><institution-id institution-id-type="GRID">grid.415967.8</institution-id><institution-id institution-id-type="ISNI">0000 0000 9965 1030</institution-id><institution>Leeds Teaching Hospitals NHS Trust, </institution></institution-wrap>Leeds, UK </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01nrxwf90</institution-id><institution-id institution-id-type="GRID">grid.4305.2</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 7988</institution-id><institution>University of Edinburgh, </institution></institution-wrap>Edinburgh, UK </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/009kr6r15</institution-id><institution-id institution-id-type="GRID">grid.417068.c</institution-id><institution-id institution-id-type="ISNI">0000 0004 0624 9907</institution-id><institution>Edinburgh Cancer Centre, </institution><institution>Western General Hospital, NHS Lothian, </institution></institution-wrap>Edinburgh, UK </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/03pvr2g57</institution-id><institution-id institution-id-type="GRID">grid.411760.5</institution-id><institution-id institution-id-type="ISNI">0000 0001 1378 7891</institution-id><institution>Department of Gynecology, </institution><institution>University Hospital W&#x000fc;rzburg, </institution></institution-wrap>W&#x000fc;rzburg, Germany </aff><aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01x29t295</institution-id><institution-id institution-id-type="GRID">grid.433867.d</institution-id><institution-id institution-id-type="ISNI">0000 0004 0476 8412</institution-id><institution>Department of Hematology and Oncology, </institution><institution>Vivantes Klinikum Am Urban, </institution></institution-wrap>Berlin, Germany </aff><aff id="Aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/03h7r5v07</institution-id><institution-id institution-id-type="GRID">grid.8142.f</institution-id><institution-id institution-id-type="ISNI">0000 0001 0941 3192</institution-id><institution>Unit of Oncology, Comprehensive Cancer Center, </institution><institution>Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Universit&#x000e0; Cattolica del Sacro Cuore, </institution></institution-wrap>Rome, Italy </aff><aff id="Aff8"><label>8</label>Ospedale Isola Tiberina &#x02013; Gemelli Isola, Rome, Italy </aff><aff id="Aff9"><label>9</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05xxs2z38</institution-id><institution-id institution-id-type="GRID">grid.411062.0</institution-id><institution-id institution-id-type="ISNI">0000 0000 9788 2492</institution-id><institution>Department of Medical Oncology, </institution><institution>Hospital Universitario Virgen de La Victoria, IBIMA, </institution></institution-wrap>M&#x000e1;laga, Spain </aff><aff id="Aff10"><label>10</label>IQVIA, Frankfurt, Germany </aff><aff id="Aff11"><label>11</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/040g76k92</institution-id><institution-id institution-id-type="GRID">grid.482783.2</institution-id><institution>IQVIA, </institution></institution-wrap>London, UK </aff><aff id="Aff12"><label>12</label>Landmark Science, Los Angeles, CA USA </aff><aff id="Aff13"><label>13</label>IQVIA, Lisbon, Portugal </aff><aff id="Aff14"><label>14</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01qhj1g70</institution-id><institution-id institution-id-type="GRID">grid.488273.2</institution-id><institution-id institution-id-type="ISNI">0000 0004 0623 5599</institution-id><institution>Daiichi Sankyo Europe GmbH, </institution></institution-wrap>Munich, Germany </aff><aff id="Aff15"><label>15</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/04r9x1a08</institution-id><institution-id institution-id-type="GRID">grid.417815.e</institution-id><institution-id institution-id-type="ISNI">0000 0004 5929 4381</institution-id><institution>Oncology Outcomes Research, Global Medical Affairs, Oncology Business Unit, </institution><institution>AstraZeneca, </institution></institution-wrap>Cambridge, UK </aff><aff id="Aff16"><label>16</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/04r9x1a08</institution-id><institution-id institution-id-type="GRID">grid.417815.e</institution-id><institution-id institution-id-type="ISNI">0000 0004 5929 4381</institution-id><institution>Medical Communications and Information, Global Medical Affairs, Oncology Business Unit, </institution><institution>AstraZeneca, </institution></institution-wrap>Cambridge, UK </aff></contrib-group><pub-date pub-type="epub"><day>20</day><month>10</month><year>2024</year></pub-date><pub-date pub-type="pmc-release"><day>20</day><month>10</month><year>2024</year></pub-date><pub-date pub-type="ppub"><year>2025</year></pub-date><volume>209</volume><issue>2</issue><fpage>419</fpage><lpage>430</lpage><history><date date-type="received"><day>26</day><month>6</month><year>2024</year></date><date date-type="accepted"><day>3</day><month>10</month><year>2024</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2024</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><abstract id="Abs1"><sec><title>Purpose</title><p id="Par1">To characterize real-world attrition rates across first-line (1L) to third-line (3L) therapies in patients with HER2-positive (HER2&#x02009;+) metastatic breast cancer (mBC) receiving routine care in seven hospital systems across Europe (France, Germany, Italy, Spain, and the UK).</p></sec><sec><title>Methods</title><p id="Par2">This retrospective, observational, multi-country, cohort study collected electronic medical record data from women aged&#x02009;&#x02265;&#x02009;18 years diagnosed with HER2&#x02009;+&#x02009;mBC from 2017&#x02013;2021. The primary endpoint was attrition rate (the proportion of patients receiving a line of therapy [LOT] with no further evidence of subsequent LOTs). Key additional endpoints included treatment patterns, real-world time to treatment discontinuation (TTD), and time to next treatment (TTNT).</p></sec><sec><title>Results</title><p id="Par3">29.6% (95% confidence interval [CI] 25.0&#x02013;34.6) and 34.2% (95% CI 27.5&#x02013;41.5) of treated patients with HER2&#x02009;+&#x02009;mBC had no further evidence of treatment beyond 1L and second-line (2L) therapy, respectively. Attrition was primarily owing to death, move to end-of-life palliative care, loss to follow up, and &#x0201c;other&#x0201d; reasons. Treatment patterns were generally aligned with clinical guidelines. Decreases in TTD (12.1 months [95% CI 10.4&#x02013;14.5] for 1L, 8.9 months [95% CI 7.3&#x02013;11.9] for 2L, 6.4 months [95% CI 5.2&#x02013;8.9] for 3L) and TTNT (15.4&#x000a0;months [95% CI 13.6&#x02013;20.6] for 1L, 13.5&#x000a0;months [95% CI 10.8&#x02013;19.4] for 2L) were observed with each subsequent LOT.</p></sec><sec><title>Conclusion</title><p id="Par4">Results unveil a large proportion of patients who do not benefit from state-of-the-art subsequent LOT, and suggest diminishing effectiveness with each subsequent LOT.</p></sec><sec><title>Supplementary Information</title><p>The online version contains supplementary material available at 10.1007/s10549-024-07506-4.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Breast neoplasm</kwd><kwd>Neoplasm metastasis</kwd><kwd>ERBB2 protein</kwd><kwd>HER2</kwd><kwd>Real-world data</kwd><kwd>Attrition</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100004325</institution-id><institution>AstraZeneca</institution></institution-wrap></funding-source></award-group></funding-group><funding-group><award-group><funding-source><institution>Daiichi Sankyo</institution></funding-source></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Springer Science+Business Media, LLC, part of Springer Nature 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par27">Breast cancer (BC) is the most common malignancy among women in European Union countries, with a total of 374,800 cases in 2022, accounting for 29.4% of all cancer diagnoses [<xref ref-type="bibr" rid="CR1">1</xref>]. Approximately 20% of all BC cases have HER2-positive (HER2&#x02009;+) disease [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR3">3</xref>], an aggressive subtype associated with poorer outcomes and higher mortality rates than HER2-negative disease [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR5">5</xref>].</p><p id="Par28">The introduction of HER2-directed therapies has contributed to improved clinical outcomes for patients with HER2&#x02009;+&#x02009;metastatic breast cancer (mBC) compared with previous standard-of-care therapies [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR6">6</xref>&#x02013;<xref ref-type="bibr" rid="CR10">10</xref>]; however, there is substantial drug-sequencing heterogeneity [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR12">12</xref>]. Online resource <xref rid="MOESM1" ref-type="media">1</xref> summarizes the HER2-directed agents approved for use in patients with HER2&#x02009;+&#x02009;mBC. Despite the introduction of HER2-directed therapies, patients frequently experience disease relapse and require subsequent lines of therapy (LOTs) [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR13">13</xref>].</p><p id="Par29">Each subsequent LOT for patients with HER2&#x02009;+&#x02009;mBC is associated with shorter treatment durations and poorer efficacy than previous LOTs [<xref ref-type="bibr" rid="CR14">14</xref>]. Receiving the optimal targeted therapy in the earliest indicated setting is important to maximize the likelihood of durable clinical benefit [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR16">16</xref>]. If patients do not receive guideline-directed care in the earliest indicated setting, the benefit gained from subsequent LOTs may be diminished or they may not receive a subsequent LOT [<xref ref-type="bibr" rid="CR17">17</xref>&#x02013;<xref ref-type="bibr" rid="CR19">19</xref>]. There is a paucity of literature reporting attrition rates among patients with HER2&#x02009;+&#x02009;mBC, with limited real-world studies conducted across European countries showing the proportion of patients with HER2&#x02009;+&#x02009;mBC receiving a subsequent LOT decreasing from first-line (1L) to fourth-line treatment [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR20">20</xref>]. As more therapies become available, understanding treatment patterns and sequencing may help guide treatment decision-making and inform the optimal treatment paradigm for patients with HER2&#x02009;+&#x02009;mBC [<xref ref-type="bibr" rid="CR11">11</xref>].</p><p id="Par30"> The study aim was to characterize real-world attrition rates across 1L to third-line (3L) therapies in patients diagnosed with HER2&#x02009;+&#x02009;mBC between 2017 and 2021 who received routine care in France, Germany, Italy, Spain, and the UK.</p></sec><sec id="Sec2"><title>Methods</title><p id="Par31">This was a retrospective, observational, multi-country, multicenter, cohort study describing attrition rates among patients with HER2&#x02009;+&#x02009;mBC using electronic medical record (EMR) data from seven hospital groups in five European countries. Online resource <xref rid="MOESM1" ref-type="media">2</xref> shows the study design.</p><sec id="Sec3"><title>Data sources</title><p id="Par32">Eligible patients were identified from IQVIA&#x02019;s Oncology Evidence Network centers within European countries (one hospital in France, two hospital groups in Germany, one hospital in Italy, one hospital group in Spain, and two hospital groups in the UK). Centers were selected based on their extensive experience in treating patients with BC and the feasibility of gathering EMR data. Details about each center are available in Online resource <xref rid="MOESM1" ref-type="media">3</xref>.</p><p id="Par33">BC diagnosis, metastatic status, hormone receptor (HR), and HER2 status were derived from diagnosis codes, tumor staging, and diagnostic tests reported in each center&#x02019;s EMRs, along with age and sex at birth. Patients had histologically confirmed BC with metastases and were identified using the International Classification of Diseases, 10th Revision, and Clinical Modification codes within the malignant neoplasm of breast hierarchy. The Union for International Cancer Control staging was used to determine metastatic disease.</p><p id="Par34">Structured EMR data and manually abstracted unstructured data (patient medical charts) were curated, cleaned, and quality checked according to center-specific standards. Data were harmonized across centers using a common data model and were collected for all systemic treatments. The information captured for each LOT was based on treatment start and end dates, as well as individual drug(s), drug regimen(s), and drug class(es) contributing to each LOT.</p></sec><sec id="Sec4"><title>Study population</title><p id="Par35">Women were eligible for study inclusion if they had histologically confirmed BC with initial metastatic (Stage IV) or early-stage disease that later became metastatic between January 01, 2017, and June 30, 2021, and were&#x02009;&#x02265;&#x02009;18 years old at the time of metastatic disease. Patients were required to have a locally determined HER2 immunohistochemistry value of 3&#x02009;+&#x02009;or a ratio of&#x02009;&#x02265;&#x02009;2.0 by in situ hybridization (ISH) or fluorescence ISH closest to the date of metastasis. Participation in any interventional clinical trial on or after the date of metastasis, presence of other co-malignancies within 1 year prior to the metastasis date, except non-melanoma skin cancer and in-situ or benign neoplasms, the capture of incomplete treatment pathway information, or opting out of re-use of data, were exclusionary.</p><p id="Par36">Patients were followed up from treatment initiation (LOT initiation/index date), until the outcome of interest, a censoring event, or the end of the study period (June 30, 2022), whichever occurred first. Based on precision estimates for the primary endpoint and a preliminary feasibility survey of eligible patient numbers at each center, a target of 100 patients per country was set.</p></sec><sec id="Sec5"><title>Endpoints</title><p id="Par37">The primary endpoint was attrition rate, defined as the proportion of patients receiving a LOT with no further evidence in EMRs of subsequent LOTs, calculated from 1L to second-line (2L) and 2L to 3L. Figure&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref> shows the equation used to calculate attrition rates.<fig id="Fig1"><label>Fig.&#x000a0;1</label><caption><p>Attrition algorithm. <italic>A</italic> attrition, <italic>FU</italic> follow up, <italic>HER2</italic>&#x02009;+&#x02009;human epidermal growth factor receptor 2-positive, <italic>LOT</italic> line of therapy, <italic>mBC</italic> metastatic breast cancer, <italic>N</italic> number of patients</p></caption><graphic xlink:href="10549_2024_7506_Fig1_HTML" id="MO1"/></fig></p><p id="Par38">LOTs were derived algorithmically referencing the European Society for Medical Oncology (ESMO) guidelines [<xref ref-type="bibr" rid="CR21">21</xref>]. The treatment holiday window was determined based on input from IQVIA&#x02019;s Medical Director; re-initiation of the same drug within a treatment gap of 365 days from the last treatment end date for that drug did not advance the LOT. The LOT algorithm was validated manually for a sample of <italic>n</italic>&#x02009;=&#x02009;100 patients from France, Germany, and the UK, and by two sensitivity analyses (Online resource <xref rid="MOESM1" ref-type="media">4</xref>). The final LOT algorithm was applied to each oncology center&#x02019;s data to ensure consistency of interpretation.</p><p id="Par39">Documented reasons for attrition included death or move to end-of-life (EOL) palliative care (within 30 days of end of LOT), discontinuation owing to toxicity, end of study period, loss to follow up (FU), or &#x0201c;other.&#x0201d; Reasons were classified as &#x0201c;other&#x0201d; if they did not meet any of the categories defined above, or if death or move to EOL palliative care occurred&#x02009;&#x0003e;&#x02009;30 days after treatment discontinuation. The 30-day window was selected following discussions with a Senior Epidemiologist and IQVIA&#x02019;s Medical Director to maximize the chance of identifying true drivers of treatment cessation, as events including death, move to EOL palliative care, and toxicities are less likely to be attributable to treatment cessation beyond this window. In the very rare occasion when more than one reason for attrition occurred within 30 days of treatment discontinuation, the most relevant, severe, and/or terminal reason (death) was recorded as the reason for attrition.</p><p id="Par40">Key secondary analyses included characterizing: (1) time to discontinuation (TTD, the length of time from the index date to subsequent LOT initiation, death, censoring at the last known activity date at the oncology center or end of the study period, whichever came first) for 1L to 3L, (2) demographic and clinical characteristics, and (3) treatment patterns. Drugs were categorized by treatment class, including HER2-directed therapies, endocrine therapy, chemotherapy (e.g., taxanes, platinum-based compounds, others), cyclin-dependent-kinase 4/6 inhibitors (CDK4/6i), endocrine therapy&#x02009;+&#x02009;CDK4/6i, and other. Treatments were flagged as maintenance therapy if they could be categorically identified as such; therefore, if pertuzumab and/or trastuzumab were used in 1L therapy, patients were not flagged for maintenance owing to the inability to identify whether these drugs were administered as part of 1L or maintenance therapy.</p><p id="Par41">Exploratory analyses included characterizing: (1) time to next treatment (TTNT, the time from the LOT start date to subsequent LOT initiation, death, censoring at the last known activity date at the oncology center or end of study, whichever occurred first) for 1L to 2L, (2) progression-free survival (PFS, the time from LOT start date to a progression or death event, censoring at the subsequent LOT initiation, last known activity date at the oncology center, or end of study period, whichever occurred first) for 1L to 3L, and (3) factors associated with receiving a subsequent LOT identified by statistical models.</p></sec><sec id="Sec6"><title>Analytical plan</title><p id="Par42">Descriptive statistics were used to summarize treatment patterns and demographic and clinical characteristics. Continuous variables were outlined by providing the number of observations, mean and standard deviation, median, interquartile ranges (IQRs), and overall ranges. Categorical variables were summarized by providing counts and proportions, with missing data considered a separate category. Point estimates and 95% confidence intervals (CIs) are presented. For time-to-event outcomes, median time to event, 95% CIs, and 6-, 12- and 18-month probabilities were estimated. Univariate and multivariable Cox proportional hazard regression models were fitted to identify variables independently associated with TTNT for 1L and 2L therapy; variables with univariate <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.1 were carried forward to multivariable models. Online resource <xref rid="MOESM1" ref-type="media">5</xref> notes the packages and workstreams used by the statistical tool R v4.1.3.</p></sec></sec><sec id="Sec7"><title>Results</title><sec id="Sec8"><title>Patient demographics and clinical characteristics</title><p id="Par43">Data from 496 women from across seven hospital groups in five European countries were included. Patient demographics and clinical characteristics are summarized in Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref> (see Online resource <xref rid="MOESM1" ref-type="media">6</xref> for data stratified by country and HR status). Median duration of FU was 41.1 months (IQR 22.4&#x02013;53.0).
<table-wrap id="Tab1"><label>Table&#x000a0;1</label><caption><p>Patient demographics and clinical characteristics</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left">Overall <italic>N</italic>&#x02009;=&#x02009;496</th></tr></thead><tbody><tr><td align="left">Median age at initial diagnosis (IQR), years</td><td char="(" align="char">56.0 (47.0&#x02013;70.0)</td></tr><tr><td align="left">Median age at mBC diagnosis (IQR), years</td><td char="(" align="char">59.0 (49.0&#x02013;72.0)</td></tr><tr><td align="left">Median BMI (IQR), kg/m<sup>2</sup></td><td char="(" align="char">25.7 (22.5&#x02013;29.7)</td></tr><tr><td align="left">Postmenopausal status at mBC diagnosis, <italic>n</italic> (%)</td><td char="(" align="char">293 (59.1)</td></tr><tr><td align="left">Current smoker,<italic> n</italic> (%)</td><td char="(" align="char">75 (15.1)</td></tr><tr><td align="left">Primary tumor type, <italic>n</italic> (%)</td><td char="." align="char"/></tr><tr><td align="left">&#x000a0;Invasive ductal carcinoma</td><td char="(" align="char">424 (85.5)</td></tr><tr><td align="left">&#x000a0;Invasive lobular carcinoma</td><td char="(" align="char">22 (4.4)</td></tr><tr><td align="left">&#x000a0;Other</td><td char="(" align="char">29 (5.9)</td></tr><tr><td align="left">&#x000a0;Unknown</td><td char="(" align="char">17 (3.4)</td></tr><tr><td align="left">&#x000a0;Missing</td><td char="(" align="char">4 (0.8)</td></tr><tr><td align="left">HR status, <italic>n</italic> (%)</td><td char="." align="char"/></tr><tr><td align="left">&#x000a0;HR&#x02009;+&#x02009;</td><td char="(" align="char">328 (66.1)</td></tr><tr><td align="left">&#x000a0;HR&#x02009;&#x02212;&#x02009;</td><td char="(" align="char">163 (32.9)</td></tr><tr><td align="left">&#x000a0;HR missing</td><td char="(" align="char">5 (1.0)</td></tr><tr><td char="(" align="char" colspan="2">Metastatic sites at BC diagnosis, <italic>n</italic><bold> (</bold>%)</td></tr><tr><td align="left">&#x000a0;&#x0003c;&#x02009;4</td><td char="(" align="char">360 (72.6)</td></tr><tr><td align="left">&#x000a0;&#x02265;&#x02009;4</td><td char="(" align="char">136 (27.4)</td></tr><tr><td align="left">Metastatic location, <italic>n</italic><bold> (</bold>%)<sup>a</sup></td><td char="." align="char"/></tr><tr><td align="left">&#x000a0;Local/breast</td><td char="(" align="char">146 (29.4)</td></tr><tr><td align="left">&#x000a0;Brain</td><td char="(" align="char">151 (30.4)</td></tr><tr><td align="left">&#x000a0;Bone</td><td char="(" align="char">285 (57.5)</td></tr><tr><td align="left">&#x000a0;Lung</td><td char="(" align="char">193 (38.9)</td></tr><tr><td align="left">&#x000a0;Liver</td><td char="(" align="char">229 (46.2)</td></tr><tr><td align="left">&#x000a0;Lymph nodes</td><td char="(" align="char">258 (52.0)</td></tr><tr><td align="left">&#x000a0;Other</td><td char="(" align="char">111 (22.4)</td></tr><tr><td align="left">Grading, <italic>n</italic> (%)</td><td char="." align="char"/></tr><tr><td align="left">&#x000a0;Grade 1</td><td char="(" align="char">3 (0.6)</td></tr><tr><td align="left">&#x000a0;Grade 2</td><td char="(" align="char">157 (31.7)</td></tr><tr><td align="left">&#x000a0;Grade 3</td><td char="(" align="char">289 (58.3)</td></tr><tr><td align="left">&#x000a0;Unknown</td><td char="(" align="char">42 (8.5)</td></tr><tr><td align="left">&#x000a0;Missing</td><td char="(" align="char">5 (1.0)</td></tr><tr><td align="left">Stage at initial BC diagnosis, <italic>n</italic><bold> (</bold>%)</td><td char="." align="char"/></tr><tr><td align="left">&#x000a0;0/I/II/III</td><td char="(" align="char">169 (34.1)</td></tr><tr><td align="left">&#x000a0;IV</td><td char="(" align="char">302 (60.9)</td></tr><tr><td align="left">&#x000a0;Unknown</td><td char="(" align="char">18 (3.6)</td></tr><tr><td align="left">&#x000a0;Missing</td><td char="(" align="char">7 (1.4)</td></tr><tr><td align="left">Total number of LOTs per patient, <italic>n</italic><bold> (</bold>%)<sup>b</sup></td><td char="." align="char"/></tr><tr><td align="left">&#x000a0;0</td><td char="(" align="char">34 (6.9)</td></tr><tr><td align="left">&#x000a0;1</td><td char="(" align="char">208 (41.9)</td></tr><tr><td align="left">&#x000a0;2</td><td char="(" align="char">131 (26.4)</td></tr><tr><td align="left">&#x000a0;3</td><td char="(" align="char">61 (12.3)</td></tr><tr><td align="left">Median duration of FU (IQR), months</td><td char="(" align="char">41.1 (22.4, 52.8)</td></tr></tbody></table><table-wrap-foot><p><italic>BMI</italic> body mass index, <italic>FU</italic> follow up, <italic>HR</italic> hormone receptor, <italic>IQR</italic> interquartile range, <italic>LOT</italic> line of therapy, <italic>mBC</italic> metastatic breast cancer</p><p><sup>a</sup>Patients may belong to&#x02009;&#x0003e;&#x02009;1 category</p><p><sup>b</sup><italic>n</italic>&#x02009;=&#x02009;62 patients received&#x02009;&#x02265;&#x02009;4 LOTs per patient</p></table-wrap-foot></table-wrap></p><p id="Par44">Median age at initial BC and mBC diagnosis was 56 (IQR 47&#x02013;70) and 59 (IQR 49&#x02013;72) years, respectively. Overall, 60.9% (<italic>n</italic>&#x02009;=&#x02009;302/496) of patients had Stage IV de-novo disease at initial BC diagnosis. Most patients were postmenopausal at mBC diagnosis (59.1%, <italic>n</italic>&#x02009;=&#x02009;293); 15.1% (<italic>n</italic>&#x02009;=&#x02009;75/496) were current smokers. Invasive ductal carcinoma was reported in 85.5% of patients (<italic>n</italic>&#x02009;=&#x02009;424/496). In total, 328 (66.1%) patients were HR&#x02013;positive, 163 (32.9%) HR&#x02013;negative, and HR status was missing for 5 (1.0%) patients. Stage IV disease was the most common stage at initial diagnosis (60.9% [<italic>n</italic>&#x02009;=&#x02009;302/496]). Overall, 77.4% of patients (<italic>n</italic>&#x02009;=&#x02009;384/496) had&#x02009;&#x02265;&#x02009;2 metastatic sites at BC diagnosis; bone (57.5%, <italic>n</italic>&#x02009;=&#x02009;285/496) and lymph node metastases (52.0%, <italic>n</italic>&#x02009;=&#x02009;258/496) were the most common; brain metastases occurred in 30.4% of patients (<italic>n</italic>&#x02009;=&#x02009;151/496).</p></sec><sec id="Sec9"><title>Treatment patterns</title><p id="Par45">Overall, 93.1% of patients (<italic>n</italic>&#x02009;=&#x02009;462/496) received at least one LOT in the metastatic setting; 51.2% of patients (<italic>n</italic>&#x02009;=&#x02009;254/496) started 2L therapy and 24.8% (<italic>n</italic>&#x02009;=&#x02009;123/496) patients started 3L therapy. In 1L 54.8% (<italic>n</italic>&#x02009;=&#x02009;253/462) of patients received HER2-directed therapy in combination with chemotherapy, in 2L 30.3% (<italic>n</italic>&#x02009;=&#x02009;77/254) of patients received a HER2-directed antibody&#x02013;drug conjugate, and in 3L 29.3% (<italic>n</italic>&#x02009;=&#x02009;36/123) of patients received HER2-directed therapy in combination with chemotherapy (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>). The most common regimens in 1L contained pertuzumab and trastuzumab in combination (65.2%, <italic>n</italic>&#x02009;=&#x02009;301/462), at 2L the most common regimens were trastuzumab emtansine-containing therapies (37.4%, <italic>n</italic>&#x02009;=&#x02009;95/254), and at 3L the most common regimens had trastuzumab as the only HER2-directed therapy (28.5%, <italic>n</italic>&#x02009;=&#x02009;35/123). Median duration of therapy was 8.0 months (IQR 3.9&#x02013;16.2) for 1L, 5.4 months (IQR 2.6&#x02013;11.9) for 2L, and 4.9 months (IQR 2.5&#x02013;9.2) for 3L; median TTD was 12.1 months (95% CI 10.4&#x02013;14.5) for 1L, 8.9 months (95% CI 7.3&#x02013;11.9) for 2L, and 6.4 months (95% CI 5.2&#x02013;8.9) for 3L. The proportion of patients with ongoing 1L or 2L treatment at end of study was 22.3% (<italic>n</italic>&#x02009;=&#x02009;103/462) and 27.2% (<italic>n</italic>&#x02009;=&#x02009;69/254), respectively.<fig id="Fig2"><label>Fig.&#x000a0;2</label><caption><p>Treatment patterns on a regimen level from 1 to 3L. <italic>1L</italic> first line, <italic>2L</italic> second line, <italic>3L</italic> third line, <italic>CDK4/6i</italic> cyclin-dependent kinase 4 and 6 inhibitor, <italic>IO</italic> immunotherapy</p></caption><graphic xlink:href="10549_2024_7506_Fig2_HTML" id="MO2"/></fig></p></sec><sec id="Sec10"><title>Attrition rates across LOT</title><p id="Par46">Overall attrition rates from 1 to 2L and 2L to 3L were 29.6% (<italic>n</italic>&#x02009;=&#x02009;107/361 [95% CI 25.0&#x02013;34.6]) and 34.2% (<italic>n</italic>&#x02009;=&#x02009;64/187 [95% CI 27.5&#x02013;41.5]), respectively (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>, Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>). Attrition rate data stratified by country and HR status are reported in Online resource <xref rid="MOESM1" ref-type="media">7</xref>. Death (37.4%, <italic>n</italic>&#x02009;=&#x02009;40) accounted for the majority of 1L to 2L attrition, followed by &#x0201c;other&#x0201d; (29.9%, <italic>n</italic>&#x02009;=&#x02009;32) and EOL palliative care (15.0%, <italic>n</italic>&#x02009;=&#x02009;16); &#x0201c;other&#x0201d; (40.6%, <italic>n</italic>&#x02009;=&#x02009;26) and death (25.0%, <italic>n</italic>&#x02009;=&#x02009;16) were the most common reasons for 2L to 3L attrition (Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>).
<table-wrap id="Tab2"><label>Table&#x000a0;2</label><caption><p>Overall attrition rates between LOT</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left">Overall <italic>N</italic>&#x02009;=&#x02009;496</th></tr></thead><tbody><tr><td align="left">1L to 2L</td><td align="left"/></tr><tr><td align="left">&#x000a0;Start of 1L, <italic>n</italic></td><td align="left">462</td></tr><tr><td align="left">&#x000a0;Completed 1L,<italic> n</italic></td><td align="left">361</td></tr><tr><td align="left">&#x000a0;Attrition rate, % (95% CI)</td><td align="left">29.6 (25.0&#x02013;34.6)</td></tr><tr><td align="left">2L to 3L</td><td align="left"/></tr><tr><td align="left">&#x000a0;Start of 2L, <italic>n</italic></td><td align="left">254</td></tr><tr><td align="left">&#x000a0;Completed 2L, <italic>n</italic></td><td align="left">187</td></tr><tr><td align="left">&#x000a0;Attrition rate, % (95% CI)</td><td align="left">34.2 (27.5&#x02013;41.5)</td></tr></tbody></table><table-wrap-foot><p><italic>1L</italic> first line, <italic>2L</italic> second line, <italic>3L</italic> third line, <italic>CI</italic> confidence interval, <italic>LOT</italic> line of therapy</p></table-wrap-foot></table-wrap><fig id="Fig3"><label>Fig.&#x000a0;3</label><caption><p>Attrition rates from 1L to 2L and 2L to 3L in the overall cohort. <italic>1L</italic> first line, <italic>2L</italic> second line, <italic>3L</italic> third line, <italic>CI</italic> confidence interval</p></caption><graphic xlink:href="10549_2024_7506_Fig3_HTML" id="MO3"/></fig><table-wrap id="Tab3"><label>Table&#x000a0;3</label><caption><p>Overall reasons for attrition between LOT</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left"><italic>n</italic></th><th align="left">Attrition rate</th></tr><tr><th align="left"/><th align="left"/><th align="left">% (95% CI)</th></tr></thead><tbody><tr><td align="left">1L to 2L</td><td align="left"/><td align="left"/></tr><tr><td align="left">&#x000a0;Death</td><td char="." align="char">40</td><td char="(" align="char">37.4 (28.2&#x02013;47.3)</td></tr><tr><td align="left">&#x000a0;EOL palliative care</td><td char="." align="char">16</td><td char="(" align="char">15.0 (8.8&#x02013;23.1)</td></tr><tr><td align="left">&#x000a0;Toxicity</td><td char="." align="char">2</td><td char="(" align="char">1.9 (0.2&#x02013;6.6)</td></tr><tr><td align="left">&#x000a0;Loss to FU</td><td char="." align="char">15</td><td char="(" align="char">14.0 (8.1&#x02013;22.1)</td></tr><tr><td align="left">&#x000a0;End of study period</td><td char="." align="char">2</td><td char="(" align="char">1.9 (0.2&#x02013;6.6)</td></tr><tr><td align="left">&#x000a0;Other</td><td char="." align="char">32</td><td char="(" align="char">29.9 (21.4&#x02013;39.5)</td></tr><tr><td align="left">2L to 3L</td><td align="left"/><td align="left"/></tr><tr><td align="left">&#x000a0;Death</td><td char="." align="char">16</td><td char="(" align="char">25.0 (15.0&#x02013;37.4)</td></tr><tr><td align="left">&#x000a0;EOL palliative care</td><td char="." align="char">6</td><td char="(" align="char">9.4 (3.5&#x02013;19.3)</td></tr><tr><td align="left">&#x000a0;Toxicity</td><td char="." align="char">3</td><td char="(" align="char">4.7 (1.0&#x02013;13.1)</td></tr><tr><td align="left">&#x000a0;Loss to FU</td><td char="." align="char">8</td><td char="(" align="char">12.5 (5.6&#x02013;23.2)</td></tr><tr><td align="left">&#x000a0;End of study period</td><td char="." align="char">5</td><td char="(" align="char">7.8 (2.6&#x02013;17.3)</td></tr><tr><td align="left">&#x000a0;Other</td><td char="." align="char">26</td><td char="(" align="char">40.6 (28.5&#x02013;53.6)</td></tr></tbody></table><table-wrap-foot><p><italic>1L</italic> first line, <italic>2L</italic> second line, <italic>3L</italic> third line, <italic>CI</italic> confidence interval, <italic>EOL</italic> end of life, <italic>FU</italic> follow up, <italic>LOT</italic> line of therapy</p></table-wrap-foot></table-wrap></p><p id="Par47">A post-hoc analysis of the &#x0201c;other&#x0201d; category identified that some patients were categorized as &#x0201c;other&#x0201d; owing to the 30-day event window in the reason for attrition algorithm (Online resource <xref rid="MOESM1" ref-type="media">8</xref>). When the window is extended beyond 30 days, we observed an increased proportion of patients with EOL palliative care, loss to FU, or death as the reason for attrition. Further, a minority of patients in the &#x0201c;other&#x0201d; category were identified as discontinuing treatment owing to stable disease, patient choice, and deteriorating condition.</p></sec><sec id="Sec11"><title>TTNT from 1 to 2L</title><p id="Par48">Median TTNT was 15.4 months (95% CI 13.6&#x02013;20.6) for 1L and 13.5 months (95% CI 10.8&#x02013;19.4) for 2L (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>). Multivariable time-to-event models with stepwise selection identified age, number of sites of metastases at BC diagnosis, and grade as being associated with TTNT (Table&#x000a0;<xref rid="Tab4" ref-type="table">4</xref>). For 1L, patients with Grade 3 disease had a longer TTNT versus Grade&#x02009;&#x02264;&#x02009;2 (hazard ratio 0.77 [95% CI 0.60&#x02013;0.99; <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.043]). For 2L, premenopausal status at mBC diagnosis was associated with a longer TTNT than postmenopausal status (hazard ratio 0.66 [95% CI 0.44&#x02013;0.98; <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.042]). Similarly, longer TTNT at 1L and 2L was associated with one site versus&#x02009;&#x02265;&#x02009;2 sites of metastases at BC diagnosis (hazard ratio 0.73 [95% CI 0.54&#x02013;0.99]; <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.045 and hazard ratio 0.48 [95% CI 0.28&#x02013;0.82]; <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.007, respectively). See online resources <xref rid="MOESM1" ref-type="media">9</xref>&#x02013;<xref rid="MOESM1" ref-type="media">11</xref> for 1L and 2L univariate time-to-event models, and PFS.<fig id="Fig4"><label>Fig.&#x000a0;4</label><caption><p>TTNT from 1 to 3L. <italic>1L</italic> first line, <italic>2L</italic> second line, <italic>CI</italic> confidence interval, <italic>LOT</italic> line of therapy, <italic>TTNT</italic> time to next treatment</p></caption><graphic xlink:href="10549_2024_7506_Fig4_HTML" id="MO4"/></fig><table-wrap id="Tab4"><label>Table&#x000a0;4</label><caption><p>Factors associated with TTNT<sup>a</sup></p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="2"/><th align="left">Hazard ratio (95% CI)</th><th align="left"><italic>P</italic> value<sup>b</sup></th></tr></thead><tbody><tr><td align="left" colspan="4">1L</td></tr><tr><td align="left" rowspan="4">&#x000a0;Age (years)</td><td align="left">&#x02009;&#x0003c;&#x02009;50</td><td align="left">Reference</td><td align="left"/></tr><tr><td align="left">50&#x02013;&#x02009;&#x02264;&#x02009;60</td><td align="left">0.90 (0.65&#x02013;1.24)</td><td char="." align="char">0.509</td></tr><tr><td align="left">60&#x02013;&#x02009;&#x02264;&#x02009;70</td><td align="left">0.77 (0.57&#x02013;1.04)</td><td char="." align="char">0.087</td></tr><tr><td align="left">&#x02009;&#x02265;&#x02009;70</td><td align="left">1.36 (0.89&#x02013;2.06)</td><td char="." align="char">0.152</td></tr><tr><td align="left" rowspan="2">&#x000a0;Number of sites of metastases at BC diagnosis</td><td align="left">&#x02009;&#x02265;&#x02009;2</td><td align="left">Reference</td><td align="left"/></tr><tr><td align="left">1</td><td align="left">0.73 (0.54&#x02013;0.99)</td><td char="." align="char">0.045</td></tr><tr><td align="left" rowspan="3">&#x000a0;Grade</td><td align="left">Grade 1&#x02013;2</td><td align="left">Reference</td><td char="." align="char"/></tr><tr><td align="left">Grade 3</td><td align="left">0.77 (0.60&#x02013;0.99)</td><td char="." align="char">0.043</td></tr><tr><td align="left">Unknown</td><td align="left">0.63 (0.39&#x02013;1.02)</td><td char="." align="char">0.059</td></tr><tr><td align="left" colspan="4">2L</td></tr><tr><td align="left" rowspan="2">&#x000a0;Number of sites of metastases at BC diagnosis</td><td align="left">&#x02009;&#x02265;&#x02009;2</td><td align="left">Reference</td><td align="left"/></tr><tr><td align="left">1</td><td align="left">0.48 (0.28&#x02013;0.28)</td><td char="." align="char">0.007</td></tr><tr><td align="left" rowspan="3">&#x000a0;Menopausal status at mBC diagnosis</td><td align="left">Postmenopausal</td><td align="left">Reference</td><td align="left"/></tr><tr><td align="left">Premenopausal</td><td align="left">0.66 (0.44&#x02013;0.98)</td><td char="." align="char">0.042</td></tr><tr><td align="left">Unknown</td><td align="left">0.52 (0.29&#x02013;0.93)</td><td char="." align="char">0.029</td></tr></tbody></table><table-wrap-foot><p><italic>1L</italic> first line, <italic>2L</italic> second line, <italic>BC</italic> breast cancer, <italic>CI</italic> confidence interval, <italic>mBC</italic> metastatic breast cancer, <italic>TTNT</italic> time to next treatment</p><p><sup>a</sup>Multivariable Cox regression model using variables carried forward from Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref> if evidence of association (<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.1) with TTNT in univariate analyses</p><p><sup>b</sup><italic>P</italic>-value derived from two-sided Wald test</p></table-wrap-foot></table-wrap></p></sec></sec><sec id="Sec12"><title>Discussion</title><p id="Par49">In this cohort of patients with HER2&#x02009;+&#x02009;mBC across seven hospital groups in Europe, 29.6% and 34.2% of treated patients had no further evidence of treatment beyond 1L and 2L therapy, respectively. Attrition was primarily owing to death, move to EOL palliative care, loss to FU, and &#x0201c;other&#x0201d; reasons. &#x0201c;Other&#x0201d; reasons accounted for 29.9% of 1L to 2L attrition (<italic>n</italic>&#x02009;=&#x02009;32) and was the most common reason for attrition between 2L and 3L (40.6%, <italic>n</italic>&#x02009;=&#x02009;26). Median treatment duration decreased with each LOT (8.0 months [IQR 3.9&#x02013;16.2] for 1L, 5.4 months [IQR 2.6&#x02013;11.9] for 2L, and 4.9 months [IQR 2.5&#x02013;9.2] for 3L).</p><p id="Par50">HER2-directed regimens are recommended for 1L and 2L treatment of patients with HER2&#x02009;+&#x02009;mBC, regardless of HR status, per ESMO and national guidelines [<xref ref-type="bibr" rid="CR21">21</xref>&#x02013;<xref ref-type="bibr" rid="CR26">26</xref>]. In this study 1L regimens were generally aligned with clinical guidelines; 65.2% of patients (<italic>n</italic>&#x02009;=&#x02009;301/462) received regimens containing pertuzumab&#x02013;trastuzumab combination therapy, reflecting the pertuzumab&#x02009;+&#x02009;trastuzumab&#x02009;+&#x02009;docetaxel regimen approved for 1L treatment of adult patients with HER2&#x02009;+&#x02009;mBC based on results from the CLEOPATRA trial [<xref ref-type="bibr" rid="CR27">27</xref>]. First-line median PFS in this study (18.9 months [95% CI 15.4&#x02013;23.0]) was similar to median PFS in the CLEOPATRA trial (18.5 months [hazard ratio for progression or death 0.62; 95% CI 0.51&#x02013;0.75, <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001]) (Online resource <xref rid="MOESM1" ref-type="media">11</xref>) [<xref ref-type="bibr" rid="CR6">6</xref>]. However, 14.5% (<italic>n</italic>&#x02009;=&#x02009;67/462) of patients at 1L and 11.4% (<italic>n</italic>&#x02009;=&#x02009;29/254) at 2L in our study did not receive HER2-directed therapies and were treated with chemotherapy/targeted therapies only, endocrine monotherapy, or other treatments.</p><p id="Par51">Limited real-world studies in patients with HER2&#x02009;+&#x02009;mBC in Europe have reported substantial attrition across LOTs [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR28">28</xref>, <xref ref-type="bibr" rid="CR29">29</xref>], with two studies showing an increase in attrition as patients moved from first- to later-lines, in agreement with our study [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR20">20</xref>]. A study in France (<italic>n</italic>&#x02009;=&#x02009;6030) reported a 52% decrease in the proportion of patients treated from 1 to 3L [<xref ref-type="bibr" rid="CR9">9</xref>], and a study in the Netherlands (<italic>n</italic>&#x02009;=&#x02009;289) estimated that 70&#x02013;80%, 51&#x02013;66%, and 33&#x02013;54% of patients who started 1L treatment went on to start 2L, 3L and 4L treatment, respectively [<xref ref-type="bibr" rid="CR20">20</xref>]. To our knowledge, all European real-world studies have demonstrated significant attrition across 1L to 3L [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR28">28</xref>, <xref ref-type="bibr" rid="CR29">29</xref>]. Whilst the current study reported an increasing proportion of patients with HER2&#x02009;+&#x02009;mBC receiving a LOT with no further evidence of subsequent LOT across 1L to 3L, the German PRAEGNANT study (<italic>n</italic>&#x02009;=&#x02009;776) reported less attrition from 2 to 3L (17.4%) compared with 1L to 2L (31.1%) [<xref ref-type="bibr" rid="CR28">28</xref>]. A chart review study by Colomer et al. (undertaken in Spain, Italy, the Netherlands) reported that the proportion of patients who started a LOT, including those ongoing therapy, who did not receive subsequent antitumor treatment was substantial but similar at 1L and 2L (45% and 42%, respectively) [<xref ref-type="bibr" rid="CR29">29</xref>]. A retrospective cohort study of patients with HER2&#x02009;+&#x02009;mBC (N&#x02009;=&#x02009;710) in an Italian hospital reported similar trends to the current study; median treatment duration was longer at 1L (15.3 [95% CI 13.4&#x02013;17.6]) but similar at 2L (5.9 months [95% CI 5.0&#x02013;8.7]) [<xref ref-type="bibr" rid="CR14">14</xref>]. A French personalized reimbursement model database showed that&#x02009;~&#x02009;30% of patients were not treated with guideline-recommended therapies in 1L, despite increased use of HER2-directed treatments during 2017&#x02013;2018 versus 2011&#x02013;2017 reflecting updated guidelines for patients with HER2&#x02009;+&#x02009;mBC in Europe, [<xref ref-type="bibr" rid="CR9">9</xref>]. This is in line with the 34.8% of patients in the current study who did not receive regimens containing pertuzumab&#x02013;trastuzumab combination therapy at 1L.</p><p id="Par52">In our study, 60.9% of patients had Stage IV de-novo disease at initial diagnosis. This is in line with recent real-world studies, which have reported de-novo (Stage IV) disease in 43.5&#x02012;61.9% of patients with HER2&#x02009;+&#x02009;mBC [<xref ref-type="bibr" rid="CR30">30</xref>&#x02013;<xref ref-type="bibr" rid="CR33">33</xref>]. The SystHERs registry study reported that patients with de-novo HER2&#x02009;+&#x02009;mBC (<italic>n</italic>&#x02009;=&#x02009;487) exhibited longer PFS and overall survival than patients with recurrent HER2&#x02009;+&#x02009;mBC (<italic>n</italic>&#x02009;=&#x02009;490) (hazard ratio 0.69 [95% CI 0.59&#x02012;0.80; <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.0001] and 0.55 [95% CI 0.44&#x02012;0.69; <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.0001], respectively) [<xref ref-type="bibr" rid="CR30">30</xref>]. The proportion of patients with Stage IV de-novo disease at initial diagnosis in our study may have inflated TTNT and impacted the attrition rates observed, compared with settings in which the proportion of de-novo cases is substantially lower.</p><p id="Par53">A decrease in TTNT was observed with each LOT (1L, 15.4 months [95% CI 13.6&#x02013;20.6]; 2L, 13.5 months [95% CI 10.8&#x02013;19.4]), as expected in patients with mBC. Patients with Grade 3 disease had a longer 1L TTNT versus Grade&#x02009;&#x02264;&#x02009;2, which could have been driven by treatment differences associated with disease severity. Patients with&#x02009;&#x02265;&#x02009;2 sites of metastases at BC diagnosis, and those with premenopausal status at mBC diagnosis, also had a longer TTNT at 2L than their peers. At 2L, median TTD was notably shorter in duration (8.9 months [95% CI 7.3&#x02013;11.9]) than median TTNT (13.5 months [95% CI 10.8&#x02013;19.4]). Disease burden often increases over time when patients undergo multiple LOTs, resulting in patients discontinuing treatment owing to lack of available treatment options and/or disease progression, which may contribute to the short TTD reported in this study.</p><p id="Par54">At study end (June 2022), tucatinib&#x02009;+&#x02009;trastuzumab&#x02009;+&#x02009;capecitabine and T-DXd monotherapy had recently been approved for&#x02009;&#x02265;&#x02009;3L treatment of patients with HER2&#x02009;+&#x02009;unresectable/mBC (2020 and 2021, respectively) [<xref ref-type="bibr" rid="CR34">34</xref>, <xref ref-type="bibr" rid="CR35">35</xref>]. T-DXd monotherapy was later approved for&#x02009;&#x02265;&#x02009;2L treatment in June 2022 [<xref ref-type="bibr" rid="CR36">36</xref>]. A small number of patients in this study received regimens containing tucatinib (at 1L <italic>n</italic>&#x02009;=&#x02009;1, at 2L <italic>n</italic>&#x02009;=&#x02009;1, at 3L <italic>n</italic>&#x02009;=&#x02009;3) or T-DXd (at 1L <italic>n</italic>&#x02009;=&#x02009;0, at 2L <italic>n</italic>&#x02009;=&#x02009;1, at 3L <italic>n</italic>&#x02009;=&#x02009;9). The SONABRE study reported improved 1L PFS and overall survival in patients diagnosed with de-novo HER2&#x02009;+&#x02009;mBC between 2013 and 2017 compared with those diagnosed between 2008 and 2012, likely related to increased use of HER2-directed therapies and the approval of pertuzumab&#x02009;+&#x02009;trastuzumab&#x02009;+&#x02009;docetaxel as a 1L treatment in 2013 [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR37">37</xref>]. Had the end date of the current study been extended to capture more patients receiving regimens containing T-DXd for&#x02009;&#x02265;&#x02009;2L treatment or regimens containing tucatinib for&#x02009;&#x02265;&#x02009;3L treatment, it is possible that TTNT and attrition rates post-2021 may have been impacted as the treatments are more efficacious than previous standard-of-care regimens prescribed between 2017 and 2021. Further research to explore the impact of the changing drug landscape on attrition rates would be insightful.</p><p id="Par55">This study has several strengths; the LOT algorithm aligns with the ESMO guidelines and was standardized across centers [<xref ref-type="bibr" rid="CR21">21</xref>], ensuring consistency. Sensitivity analyses of the robustness of the LOT algorithm performed well, with minimal variance in classification of LOTs and treatment regimens when tested under different parameters (Online resource <xref rid="MOESM1" ref-type="media">4</xref><bold>)</bold>. For all participating centers, death data were captured from EMRs linked to local or national death registries within each country, or ascertained via manual death look-up outside the EMR, resulting in a higher complete capture of death and more accurate reporting of attrition rates, PFS and TTNT than if events were captured from EMR databases alone. Key clinical and outcome data were available for these analyses as both structured and unstructured data were collected, allowing for granularity of the clinical data. Variables such as progression events that were unlikely to be captured in the structured EMR were manually abstracted from patient notes to enable appropriate capture of the events and mitigate underreporting of progression from structured data alone. Data checks were conducted to assess the degree of missingness and the extent of outlier values for key variables at the outset of analysis, with a common data model used to harmonize the data.</p><p id="Par56">This study had various limitations: heterogeneity between centers in the study and the modest sample size at each center limit interpretation of differences in patient populations attending each hospital system, clinician attitudes to and choice of treatment, access to treatments, and treatment costs. Generalizability of reasons for attrition (e.g., move to EOL care) to other European countries is constrained by the use of a small number of sites in selected European countries. Leveraging methods to ensure consistency across the centers helped minimize between-center differences in classification of attrition. Exclusive use of secondary and potentially incomplete data meant that LOTs may have been misclassified for patients who completed only part of their patient journey at the selected oncology centers. This may have played a larger role in countries with a decentralized healthcare provider structure (e.g., Germany), where patients may be treated in multiple centers, switching healthcare providers during the course of their disease. To minimize misclassification of LOT, efforts were made at each center to collect complete treatment information; patients who had clearly incomplete records were excluded. To check algorithm performance, a Medical Oncologist and an Epidemiologist reviewed a random sample of 100 patients prior to study initiation, which led to two small revisions improving algorithm performance:&#x000a0;including the (F)EC-TPH treatment regimen and allowing for intra-class drug switching. However, as not all patients&#x02019; treatment journeys were manually reviewed with respect to algorithm performance there is a chance some misclassification was introduced. Factors associated with treatment outcomes, such as details of tumor burden, disease progression, and central nervous system metastasis, may be underreported; however, this is likely to be non-differential with respect to attrition and would not qualitatively impact results. EMR databases at some centers have limited ability to capture all reasons for stopping a treatment, which do not always reflect the precluding circumstances, potentially contributing to reasons classified as &#x0201c;other.&#x0201d;</p><p id="Par57">Our definition of attrition rate excluded patients whose previous LOT was ongoing from the numerator (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>); an alternative definition that includes patients who <italic>started</italic> the previous LOT would have resulted in lower attrition rates and would not have accounted for patients remaining on an earlier LOT. Eastern Cooperative Oncology Group (ECOG) performance status is an important prognostic factor that was not collected from sites in this study, but may have impacted TTNT from 1 and 2L and from 2 to 3L. Additionally, TTNT2 (the time from the LOT start date to subsequent LOT initiation, death, censoring at the last known activity date at the oncology center or end of study, whichever occurred first) from 1 to 3L was not analysed in the current study, but may have provided useful reference for assessing treatment sequences in future research. During the study period the COVID-19 pandemic and subsequent lockdowns occurred, which may have impacted the ability of centers to provide palliative and anticancer therapy and consequently affected attrition rates. Finally, this research provides limited insights to establishing optimal treatment sequencing for patients with HER2&#x02009;+&#x02009;mBC.</p></sec><sec id="Sec13"><title>Conclusions</title><p id="Par58">Real-world attrition rates for patients with HER2&#x02009;+&#x02009;mBC in Europe are not well characterized. The results we report in this patient population show that attrition rates after 1L and 2L are high and suggest that effectiveness decreases with each subsequent LOT. This highlights the importance of implementing effective drug-sequencing strategies to provide guideline-concordant care in the earliest indicated setting, given the potential loss of opportunity with each subsequent LOT. Additional strategies to improve treatment rates may include early diagnosis of progression, prehabilitation and frailty management. Further research is needed to understand reasons for attrition not captured within the current study, which may reflect differences in patient fitness, clinical practice across centers, patient preference and attitudes to treatment (which may be related to factors such as age), and financial and regulatory barriers to accessing treatments across centers.</p></sec><sec id="Sec14" sec-type="supplementary-material"><title>Supplementary Information</title><p>Below is the link to the electronic supplementary material.<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="10549_2024_7506_MOESM1_ESM.docx"><caption><p>Supplementary file1 (DOCX 219 KB)</p></caption></media></supplementary-material></p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>1L</term><def><p id="Par5">First line</p></def></def-item><def-item><term>2L</term><def><p id="Par6">Second line</p></def></def-item><def-item><term>3L</term><def><p id="Par7">Third line</p></def></def-item><def-item><term>A</term><def><p id="Par8">Attrition</p></def></def-item><def-item><term>BC</term><def><p id="Par9">Breast cancer</p></def></def-item><def-item><term>BMI</term><def><p id="Par10">Body mass index</p></def></def-item><def-item><term>CI</term><def><p id="Par11">Confidence interval</p></def></def-item><def-item><term>COVID-19</term><def><p id="Par12">Coronavirus disease 2019</p></def></def-item><def-item><term>CDK4/6i </term><def><p id="Par13">Cyclin-dependent kinase 4 and 6 inhibitor</p></def></def-item><def-item><term>EMR</term><def><p id="Par14">Electronic medical record</p></def></def-item><def-item><term>EOL</term><def><p id="Par15">End of life</p></def></def-item><def-item><term>ESMO</term><def><p id="Par16">European Society for Medical Oncology</p></def></def-item><def-item><term>FU</term><def><p id="Par17">Follow up</p></def></def-item><def-item><term>HER2</term><def><p id="Par18">Human epidermal growth factor receptor 2</p></def></def-item><def-item><term>HR</term><def><p id="Par19">Hormone receptor</p></def></def-item><def-item><term>IO</term><def><p id="Par20">Immunotherapy</p></def></def-item><def-item><term>LOT</term><def><p id="Par21">Line of therapy</p></def></def-item><def-item><term>mBC</term><def><p id="Par22">Metastatic breast cancer</p></def></def-item><def-item><term>N</term><def><p id="Par23">Number of patients</p></def></def-item><def-item><term>PFS</term><def><p id="Par24">Progression-free survival</p></def></def-item><def-item><term>TTD</term><def><p id="Par25">Time to treatment discontinuation</p></def></def-item><def-item><term>TTNT</term><def><p id="Par26">Time to next treatment</p></def></def-item></def-list></glossary><fn-group><fn><p><bold>Publisher's Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><ack><title>Acknowledgements</title><p>The authors thank the Data Office of Institut Curie for sharing their expertise on real-world data and their involvement in data collection and quality control for this study. Medical writing support was provided by Carmen Grimaldos, PhD, and Francesca Codrington, BSc, of Helios Medical Communications, part of Helios Global Group, Cheshire, UK, which was funded by AstraZeneca in accordance with Good Publication Practice (GPP 2022) guidelines (<ext-link ext-link-type="uri" xlink:href="http://www.ismpp.org/gpp-2022">http://www.ismpp.org/gpp-2022</ext-link>). The manuscript was reviewed for medical accuracy by AstraZeneca and Daiichi Sankyo; however, the authors retained full control of the content and made the final decisions for all aspects of this article.</p></ack><notes notes-type="author-contribution"><title>Author contributions</title><p>N.H. (steering committee co-chair), N.U.L. (steering committee co-chair), M.P., N.S., and S.V. contributed to the conception and/or design of the study and development of the study protocol. N.H., N.U.L., E.C., G.J., V.M., N.N., G.V., R.B., and C.K. were members of the steering committee. M.P., H.B., and N.K.-C. were involved in data acquisition and analysis. All authors participated in the interpretation of data. All authors were involved in drafting and reviewing the manuscript for publication. All authors approved the final version of the manuscript and accept responsibility to submit for publication.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>This study is sponsored by AstraZeneca. In March 2019, AstraZeneca entered into a global development and commercialization collaboration agreement with Daiichi Sankyo for trastuzumab deruxtecan (T-DXd; DS-8201).</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>We will adhere to the ethical obligations for responsible sharing of data. The data that support the findings of this study are not publicly available due to patient privacy and legal restrictions. Requests for access to the de-identified data can be submitted to catherine.hogg@iqvia.com and grainne.long@astrazeneca.com for review and approval; however, requests for patient-level data cannot be granted due to legal and study ethics approval requirements.</p></notes><notes><title>Declarations</title><notes id="FPar1" notes-type="COI-statement"><title>Conflict of interest</title><p id="Par59">The authors declare the following competing interests: N.H. has received lecture honoraria from Art Tempi, AstraZeneca, Daiichi Sankyo, Gilead, Lilly, Medscape, MSD, Novartis, Onkowissen, Pierre Fabre, Roche, Sanofi, Seagen, Viatris, and Zuelligpharma; has received consulting or advisory honoraria from Aptitude Health, Gilead, Pfizer, Sandox-Hexal, Sanofi, and Seagen; has received research funding from AstraZeneca, Bristol Myers Squibb, Daiichi Sankyo, Gilead, MSD, Roche, Seagen, TRIO, and WSG; has participated on IDMC/steering committees for Lilly, Pierre Fabre, and Roche; and has ownership interest in the West German Study Group. E.C. has received lecture, consulting, or advisory honoraria from AstraZeneca, Daiichi Sankyo, Gilead, Lilly, Menarini, MSD, Novartis, Pfizer, Reveal Genomics, and Roche; has received support for attending meetings and/or travel from AstraZeneca, Pfizer, and Roche; has received research funding from Daiichi Sankyo, Pfizer, and Roche; and has participated on steering committees for AstraZeneca, Daiichi Sankyo, Gilead, Novartis, Reveal Genomics, and Roche. G.J. has received consulting honoraria from AbbVie, Amgen, AstraZeneca, Bristol Myers Squibb, Daiichi Sankyo, Diaccurate, Lilly, Novartis, Pfizer, Roche, and Seagen; has received honoraria from AbbVie, Amgen, AstraZeneca, Bristol Myers Squibb, Daiichi Sankyo, Lilly, Novartis, Pfizer, Roche, and Seagen; has received support for attending meetings and/or travel from Amgen, AstraZeneca Bristol Myers Squibb, Gilead, Lilly, Novartis, Pfizer, and Roche; and has received medical writing support from Amgen, AstraZeneca, Bristol Myers Squibb, Lilly, Novartis, and Roche. V.M. has received lecture honoraria from AstraZeneca, Daiichi Sankyo, Eisai, Gilead, high5 Oncology, iMED Institut, Lilly, Medac, Medscape, MSD, Novartis, Onkowissen, Pfizer, Pierre Fabre, Roche, and Seagen; has received consulting or advisory honoraria from ClinSol, Daiichi Sankyo, Eisai, Gilead, Lilly, MSD, Novartis, Pierre Fabre, PINK, Roche, and Stemline; and has received research funding from AstraZeneca, Genentech, Novartis, Roche, and Seagen. N.N. has received consulting or advisory honoraria from AstraZeneca, Chugai Pharmaceutical, and Daiichi Sankyo; has received lecture honoraria from AstraZeneca, Chugai Pharmaceutical, Eisai, Daiichi Sankyo, Eli Lilly Japan, Nippon Kayaku, and Pfizer Japan; and has received research funding from Chugai Pharmaceutical, Daiichi Sankyo, Eli Lilly Japan, Nippon Kayaku, and Pfizer Japan. G.V. has received research grants from Dako/Agilent Technologies, Roche/Genentech, and Ventana Medical Systems, and has received honoraria from AstraZeneca, Daiichi Sankyo, Dako/Agilent, Gilead, MSD Oncology, Pfizer, Roche, and Ventana. R.B. has held advisory roles at AstraZeneca, Daiichi Sankyo, Eisai, Eli Lilly, Gilead, Gr&#x000fc;nenthal, MSD, Novartis, Pfizer, Pierre Fabre, Roche, Seagen, and Stemline; has received lecture honoraria from AstraZeneca, Bristol Myers Squibb, Daiichi Sankyo, Eisai, Eli Lilly, Gilead, Gr&#x000fc;nenthal, MSD, Novartis, Pfizer, Pierre Fabre, Roche, Seagen, and Stemline; and has received research support from Daiichi Sankyo, MSD, Novartis, and Roche. C.K. has received lecture honoraria from AstraZeneca, Eli Lilly, Genomic Health, Gilead, GSK, Novartis, PharmaMar, Pfizer, and Roche; has received consulting or advisory honoraria from AstraZeneca, Eli Lilly, Genomic Health, Gilead, GSK, MSD, Novartis, PharmaMar, and Roche; and has participated on steering committees for AstraZeneca. M.J.H. has received lecture honoraria from AstraZeneca. R.M.C. has received an unrestricted educational grant from Pfizer; has received research support from AstraZeneca, Daiichi Sankyo, MSD Ireland, and Pfizer; has received honoraria from AstraZeneca, Daiichi Sankyo, Gilead, Lilly, and Seagen; and has received support for attending meetings and/or travel from Gilead, Novartis, and Roche. M.G. has received support for attending meetings and/or travel from AstraZeneca, Gilead, Roche, and Pfizer, and has received honoraria from AstraZeneca, Gilead, and Pfizer. V.G. has received honoraria from AstraZeneca, Daiichi Sankyo, Eli Lilly, Exact Sciences, Gilead, Menarini Stemline, MSD, Novartis, Pfizer, Olema Oncology, Pierre Fabre, and Roche; has received lecture honoraria from AstraZeneca, Daiichi Sankyo, Eli Lilly, Exact Sciences, Gilead, GSK, Menarini Stemline, Novartis, Roche, and Zentiva; and has received expert testimony honoraria from Eli Lilly. G.B. has received honoraria from Agendia, Amgen, AstraZeneca, Chugai Pharmaceutical, Daiichi Sankyo, Eisai, Exact Science, Gilead, Helsinn Lilly, Menarini Stemline, MSD, Novartis, Pfizer, Roche, Sanofi, and Seagen, and has received a research grant from Gilead. H.W. has received lecture honoraria from Seagen; has received consulting or advisory honoraria from AstraZeneca, Augustine Therapeutics, Daiichi Sankyo, E Squared Communications LLC, Gilead, Immutep Ltd, Lilly, MediMix, Novartis, NV Hict, Pfizer, PSI CRO, Roche, and Stemline Therapeutics; has received support for attending meetings and/or travel from Daiichi Sankyo and Pfizer; has received research funding from Novartis, Roche, and Syneos Health; and has received subscription fees from Gilead. S.E.-d-R. has received honoraria from AstraZeneca, COR2ED, Daiichi Sankyo, Jazz Pharmaceuticals, Medistream, Pierre Fabre, Roche, and Seagen; has received research funding from AstraZeneca, Byondis, Daiichi Sankyo, Jazz Pharmaceuticals, MEDSIR, Roche, SOLTI, and Zymeworks; and has received support for attending meetings and/or travel from AstraZeneca, Daiichi Sankyo, Kern Pharma, Pfizer, Seagen, and SOLTI. M.P., H.B., N.K.-C., N.S., and S.V. are employees of AstraZeneca. N.K.-C. holds stocks in AstraZeneca and AbbVie. N.U.L. has received honoraria from AstraZeneca and has received research funding from AstraZeneca. The remaining authors declare no competing interests.</p></notes><notes id="FPar2"><title>Ethical approval</title><p id="Par60">The study protocol was approved by Fondazione Policlinico Universitario Agostino Gemelli IRCCS Comitato Etico, Medizinische Ethikkommission an der Julius-Maximilians-Universit&#x000e4;t W&#x000fc;rzburg (for University Hospital Wurzburg and Vivantes Hospital Group), HRA and Health and Care Research Wales (for Leeds Teaching Hospitals Trust and NHS Lothian, UK), CEIM Provincial de M&#x000e1;laga (for Unidad de Gesti&#x000f3;n Cl&#x000ed;nica Intercentros Oncology, Spain), and Comite de Revue Interne Data (for Institut Curie, France; study MR-004 compliant).</p></notes><notes id="FPar3"><title>Consent to participate</title><p id="Par61">Not applicable.</p></notes><notes id="FPar4"><title>Consent to publish</title><p id="Par62">Not applicable.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><mixed-citation publication-type="other">European Cancer Information System (ECIS) (2022) Breast cancer in the EU. <ext-link ext-link-type="uri" xlink:href="https://ecis.jrc.ec.europa.eu/">https://ecis.jrc.ec.europa.eu/</ext-link>. Accessed 28 Nov 2023</mixed-citation></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name><surname>Morales</surname><given-names>S</given-names></name><name><surname>Gasol</surname><given-names>A</given-names></name><name><surname>Sanchez</surname><given-names>DR</given-names></name></person-group><article-title>HER2-positive cancers and antibody-based treatment: state of the art and future developments</article-title><source>Cancers</source><year>2021</year><volume>13</volume><fpage>5771</fpage><pub-id pub-id-type="doi">10.3390/cancers13225771</pub-id><pub-id pub-id-type="pmid">34830927</pub-id>
</element-citation><mixed-citation id="mc-CR2" publication-type="journal">Morales S, Gasol A, Sanchez DR (2021) HER2-positive cancers and antibody-based treatment: state of the art and future developments. Cancers (Basel) 13:5771. 10.3390/cancers13225771<pub-id pub-id-type="pmid">34830927</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name><surname>Wolff</surname><given-names>AC</given-names></name><name><surname>Hammond</surname><given-names>ME</given-names></name><name><surname>Hicks</surname><given-names>DG</given-names></name><etal/></person-group><article-title>Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update</article-title><source>J Clin Oncol</source><year>2013</year><volume>31</volume><fpage>3997</fpage><lpage>4013</lpage><pub-id pub-id-type="doi">10.1200/JCO.2013.50.9984</pub-id><pub-id pub-id-type="pmid">24101045</pub-id>
</element-citation><mixed-citation id="mc-CR3" publication-type="journal">Wolff AC, Hammond ME, Hicks DG et al (2013) Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol 31:3997&#x02013;4013. 10.1200/JCO.2013.50.9984<pub-id pub-id-type="pmid">24101045</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name><surname>Patel</surname><given-names>A</given-names></name><name><surname>Unni</surname><given-names>N</given-names></name><name><surname>Peng</surname><given-names>Y</given-names></name></person-group><article-title>The changing paradigm for the treatment of HER2-positive breast cancer</article-title><source>Cancers (Basel)</source><year>2020</year><volume>12</volume><fpage>2081</fpage><pub-id pub-id-type="doi">10.3390/cancers12082081</pub-id><pub-id pub-id-type="pmid">32731409</pub-id>
</element-citation><mixed-citation id="mc-CR4" publication-type="journal">Patel A, Unni N, Peng Y (2020) The changing paradigm for the treatment of HER2-positive breast cancer. Cancers (Basel) 12:2081. 10.3390/cancers12082081<pub-id pub-id-type="pmid">32731409</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name><surname>Howlader</surname><given-names>N</given-names></name><name><surname>Cronin</surname><given-names>KA</given-names></name><name><surname>Kurian</surname><given-names>AW</given-names></name><name><surname>Andridge</surname><given-names>R</given-names></name></person-group><article-title>Differences in breast cancer survival by molecular subtypes in the United States</article-title><source>Cancer Epidemiol Biomarkers Prev</source><year>2018</year><volume>27</volume><fpage>619</fpage><lpage>626</lpage><pub-id pub-id-type="doi">10.1158/1055-9965.EPI-17-0627</pub-id><pub-id pub-id-type="pmid">29593010</pub-id>
</element-citation><mixed-citation id="mc-CR5" publication-type="journal">Howlader N, Cronin KA, Kurian AW, Andridge R (2018) Differences in breast cancer survival by molecular subtypes in the United States. Cancer Epidemiol Biomarkers Prev 27:619&#x02013;626. 10.1158/1055-9965.EPI-17-0627<pub-id pub-id-type="pmid">29593010</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name><surname>Baselga</surname><given-names>J</given-names></name><name><surname>Cort&#x000e9;s</surname><given-names>J</given-names></name><name><surname>Kim</surname><given-names>S-B</given-names></name><etal/></person-group><article-title>Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer</article-title><source>N Engl J Med</source><year>2012</year><volume>366</volume><fpage>109</fpage><lpage>119</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1113216</pub-id><pub-id pub-id-type="pmid">22149875</pub-id>
</element-citation><mixed-citation id="mc-CR6" publication-type="journal">Baselga J, Cort&#x000e9;s J, Kim S-B et al (2012) Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 366:109&#x02013;119. 10.1056/NEJMoa1113216<pub-id pub-id-type="pmid">22149875</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><mixed-citation publication-type="other">European Medicines Agency (EMA) (2023) Perjeta: summary of product characteristics. <ext-link ext-link-type="uri" xlink:href="https://www.ema.europa.eu/en/medicines/human/EPAR/perjeta">https://www.ema.europa.eu/en/medicines/human/EPAR/perjeta</ext-link>. Accessed 18 Feb 2024</mixed-citation></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name><surname>Verma</surname><given-names>S</given-names></name><name><surname>Miles</surname><given-names>D</given-names></name><name><surname>Gianni</surname><given-names>L</given-names></name><etal/></person-group><article-title>Trastuzumab emtansine for HER2-positive advanced breast cancer</article-title><source>N Engl J Med</source><year>2012</year><volume>367</volume><fpage>1783</fpage><lpage>1791</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1209124</pub-id><pub-id pub-id-type="pmid">23020162</pub-id>
</element-citation><mixed-citation id="mc-CR8" publication-type="journal">Verma S, Miles D, Gianni L et al (2012) Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 367:1783&#x02013;1791. 10.1056/NEJMoa1209124<pub-id pub-id-type="pmid">23020162</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name><surname>Cottu</surname><given-names>P</given-names></name><name><surname>Coudert</surname><given-names>B</given-names></name><name><surname>Perol</surname><given-names>D</given-names></name><etal/></person-group><article-title>Evolution in the real-world therapeutic strategies in more than 20,000 women with breast cancer having received human epidermal growth factor receptor 2-targeted treatments: results from the French personalized reimbursement model database (2011&#x02013;2018)</article-title><source>Eur J Cancer</source><year>2020</year><volume>141</volume><fpage>209</fpage><lpage>217</lpage><pub-id pub-id-type="doi">10.1016/j.ejca.2020.10.012</pub-id><pub-id pub-id-type="pmid">33176232</pub-id>
</element-citation><mixed-citation id="mc-CR9" publication-type="journal">Cottu P, Coudert B, Perol D et al (2020) Evolution in the real-world therapeutic strategies in more than 20,000 women with breast cancer having received human epidermal growth factor receptor 2-targeted treatments: results from the French personalized reimbursement model database (2011&#x02013;2018). Eur J Cancer 141:209&#x02013;217. 10.1016/j.ejca.2020.10.012<pub-id pub-id-type="pmid">33176232</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name><surname>Slamon</surname><given-names>DJ</given-names></name><name><surname>Leyland-Jones</surname><given-names>B</given-names></name><name><surname>Shak</surname><given-names>S</given-names></name><etal/></person-group><article-title>Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2</article-title><source>N Engl J Med</source><year>2001</year><volume>344</volume><fpage>783</fpage><lpage>792</lpage><pub-id pub-id-type="doi">10.1056/NEJM200103153441101</pub-id><pub-id pub-id-type="pmid">11248153</pub-id>
</element-citation><mixed-citation id="mc-CR10" publication-type="journal">Slamon DJ, Leyland-Jones B, Shak S et al (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783&#x02013;792. 10.1056/NEJM200103153441101<pub-id pub-id-type="pmid">11248153</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name><surname>Nuzzolese</surname><given-names>I</given-names></name><name><surname>Montemurro</surname><given-names>F</given-names></name></person-group><article-title>Attrition in metastatic breast cancer: a metric to be reported in randomised clinical trials?</article-title><source>Lancet Oncol</source><year>2020</year><volume>21</volume><fpage>21</fpage><lpage>24</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(19)30792-2</pub-id><pub-id pub-id-type="pmid">31908294</pub-id>
</element-citation><mixed-citation id="mc-CR11" publication-type="journal">Nuzzolese I, Montemurro F (2020) Attrition in metastatic breast cancer: a metric to be reported in randomised clinical trials? Lancet Oncol 21:21&#x02013;24. 10.1016/S1470-2045(19)30792-2<pub-id pub-id-type="pmid">31908294</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name><surname>Rocque</surname><given-names>GB</given-names></name><name><surname>Kandhare</surname><given-names>PG</given-names></name><name><surname>Williams</surname><given-names>CP</given-names></name><etal/></person-group><article-title>Visualization of sequential treatments in metastatic breast cancer</article-title><source>JCO Clin Cancer Inform</source><year>2019</year><volume>3</volume><fpage>1</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1200/CCI.18.00095</pub-id><pub-id pub-id-type="pmid">30840488</pub-id>
</element-citation><mixed-citation id="mc-CR12" publication-type="journal">Rocque GB, Kandhare PG, Williams CP et al (2019) Visualization of sequential treatments in metastatic breast cancer. JCO Clin Cancer Inform 3:1&#x02013;8. 10.1200/CCI.18.00095<pub-id pub-id-type="pmid">30840488</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name><surname>Tapia</surname><given-names>M</given-names></name><name><surname>Hernando</surname><given-names>C</given-names></name><name><surname>Mart&#x000ed;nez</surname><given-names>MT</given-names></name><etal/></person-group><article-title>Clinical impact of new treatment strategies for HER2-positive metastatic breast cancer patients with resistance to classical anti-HER therapies</article-title><source>Cancers (Basel)</source><year>2023</year><volume>15</volume><fpage>4522</fpage><pub-id pub-id-type="doi">10.3390/cancers15184522</pub-id><pub-id pub-id-type="pmid">37760491</pub-id>
</element-citation><mixed-citation id="mc-CR13" publication-type="journal">Tapia M, Hernando C, Mart&#x000ed;nez MT et al (2023) Clinical impact of new treatment strategies for HER2-positive metastatic breast cancer patients with resistance to classical anti-HER therapies. Cancers (Basel) 15:4522. 10.3390/cancers15184522<pub-id pub-id-type="pmid">37760491</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name><surname>Mehta</surname><given-names>S</given-names></name><name><surname>Xie</surname><given-names>J</given-names></name><name><surname>Ionescu-Ittu</surname><given-names>R</given-names></name><etal/></person-group><article-title>Real-world treatment patterns and outcomes following first-line pertuzumab and trastuzumab among patients with HER2+ metastatic breast cancer</article-title><source>Oncol Ther</source><year>2023</year><volume>11</volume><fpage>481</fpage><lpage>493</lpage><pub-id pub-id-type="doi">10.1007/s40487-023-00241-8</pub-id><pub-id pub-id-type="pmid">37715853</pub-id>
</element-citation><mixed-citation id="mc-CR14" publication-type="journal">Mehta S, Xie J, Ionescu-Ittu R et al (2023) Real-world treatment patterns and outcomes following first-line pertuzumab and trastuzumab among patients with HER2+ metastatic breast cancer. Oncol Ther 11:481&#x02013;493. 10.1007/s40487-023-00241-8<pub-id pub-id-type="pmid">37715853</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name><surname>Bonotto</surname><given-names>M</given-names></name><name><surname>Gerratana</surname><given-names>L</given-names></name><name><surname>Iacono</surname><given-names>D</given-names></name><etal/></person-group><article-title>Treatment of metastatic breast cancer in a real-world scenario: is progression-free survival with first line predictive of benefit from second and later lines?</article-title><source>Oncologist</source><year>2015</year><volume>20</volume><fpage>719</fpage><lpage>724</lpage><pub-id pub-id-type="doi">10.1634/theoncologist.2015-0002</pub-id><pub-id pub-id-type="pmid">26018662</pub-id>
</element-citation><mixed-citation id="mc-CR15" publication-type="journal">Bonotto M, Gerratana L, Iacono D et al (2015) Treatment of metastatic breast cancer in a real-world scenario: is progression-free survival with first line predictive of benefit from second and later lines? Oncologist 20:719&#x02013;724. 10.1634/theoncologist.2015-0002<pub-id pub-id-type="pmid">26018662</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name><surname>Pizzuti</surname><given-names>L</given-names></name><name><surname>Krasniqi</surname><given-names>E</given-names></name><name><surname>Sperduti</surname><given-names>I</given-names></name><etal/></person-group><article-title>PANHER study: a 20-year treatment outcome analysis from a multicentre observational study of HER2-positive advanced breast cancer patients from the real-world setting</article-title><source>Ther Adv Med Oncol</source><year>2021</year><volume>13</volume><fpage>17588359211059873</fpage><pub-id pub-id-type="doi">10.1177/17588359211059873</pub-id><pub-id pub-id-type="pmid">35173816</pub-id>
</element-citation><mixed-citation id="mc-CR16" publication-type="journal">Pizzuti L, Krasniqi E, Sperduti I et al (2021) PANHER study: a 20-year treatment outcome analysis from a multicentre observational study of HER2-positive advanced breast cancer patients from the real-world setting. Ther Adv Med Oncol 13:17588359211059872. 10.1177/17588359211059873<pub-id pub-id-type="pmid">35173816</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name><surname>Manso</surname><given-names>L</given-names></name><name><surname>Sanchez-Mu&#x000f1;oz</surname><given-names>A</given-names></name><name><surname>Calvo</surname><given-names>I</given-names></name><etal/></person-group><article-title>Late administration of trastuzumab emtansine might lead to loss of chance for better outcome in patients with HER2-positive metastatic breast cancer</article-title><source>Breast Care (Basel)</source><year>2018</year><volume>13</volume><fpage>277</fpage><lpage>283</lpage><pub-id pub-id-type="doi">10.1159/000488794</pub-id><pub-id pub-id-type="pmid">30319330</pub-id>
</element-citation><mixed-citation id="mc-CR17" publication-type="journal">Manso L, Sanchez-Mu&#x000f1;oz A, Calvo I et al (2018) Late administration of trastuzumab emtansine might lead to loss of chance for better outcome in patients with HER2-positive metastatic breast cancer. Breast Care (Basel) 13:277&#x02013;283. 10.1159/000488794<pub-id pub-id-type="pmid">30319330</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name><surname>Montemurro</surname><given-names>F</given-names></name><name><surname>Ellis</surname><given-names>P</given-names></name><name><surname>Anton</surname><given-names>A</given-names></name><etal/></person-group><article-title>Safety of trastuzumab emtansine (T-DM1) in patients with HER2-positive advanced breast cancer: primary results from the KAMILLA study cohort 1</article-title><source>Eur J Cancer</source><year>2019</year><volume>109</volume><fpage>92</fpage><lpage>102</lpage><pub-id pub-id-type="doi">10.1016/j.ejca.2018.12.022</pub-id><pub-id pub-id-type="pmid">30708264</pub-id>
</element-citation><mixed-citation id="mc-CR18" publication-type="journal">Montemurro F, Ellis P, Anton A et al (2019) Safety of trastuzumab emtansine (T-DM1) in patients with HER2-positive advanced breast cancer: primary results from the KAMILLA study cohort 1. Eur J Cancer 109:92&#x02013;102. 10.1016/j.ejca.2018.12.022<pub-id pub-id-type="pmid">30708264</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name><surname>Arias</surname><given-names>LPD</given-names></name><name><surname>Teijido</surname><given-names>PG</given-names></name><name><surname>Servitja</surname><given-names>S</given-names></name><etal/></person-group><article-title>CASCADE study: pronounced decline in treatment efficacy through the metastatic life of breast cancer patients</article-title><source>Ann Oncol</source><year>2016</year><volume>27</volume><fpage>vi76</fpage><pub-id pub-id-type="doi">10.1093/annonc/mdw365.27</pub-id></element-citation><mixed-citation id="mc-CR19" publication-type="journal">Arias LPD, Teijido PG, Servitja S et al (2016) CASCADE study: pronounced decline in treatment efficacy through the metastatic life of breast cancer patients. Ann Oncol 27:vi76. 10.1093/annonc/mdw365.27</mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name><surname>Ibragimova</surname><given-names>KIE</given-names></name><name><surname>Geurts</surname><given-names>SME</given-names></name><name><surname>Meegdes</surname><given-names>M</given-names></name><etal/></person-group><article-title>Outcomes for the first four lines of therapy in patients with HER2-positive advanced breast cancer: results from the SONABRE registry</article-title><source>Breast Cancer Res Treat</source><year>2023</year><volume>198</volume><fpage>239</fpage><lpage>251</lpage><pub-id pub-id-type="doi">10.1007/s10549-022-06832-9</pub-id><pub-id pub-id-type="pmid">36635428</pub-id>
</element-citation><mixed-citation id="mc-CR20" publication-type="journal">Ibragimova KIE, Geurts SME, Meegdes M et al (2023) Outcomes for the first four lines of therapy in patients with HER2-positive advanced breast cancer: results from the SONABRE registry. Breast Cancer Res Treat 198:239&#x02013;251. 10.1007/s10549-022-06832-9<pub-id pub-id-type="pmid">36635428</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name><surname>Gennari</surname><given-names>A</given-names></name><name><surname>Andr&#x000e9;</surname><given-names>F</given-names></name><name><surname>Barrios</surname><given-names>CH</given-names></name><etal/></person-group><article-title>ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer</article-title><source>Ann Oncol</source><year>2021</year><volume>32</volume><fpage>1475</fpage><lpage>1495</lpage><pub-id pub-id-type="doi">10.1016/j.annonc.2021.09.019</pub-id><pub-id pub-id-type="pmid">34678411</pub-id>
</element-citation><mixed-citation id="mc-CR21" publication-type="journal">Gennari A, Andr&#x000e9; F, Barrios CH et al (2021) ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. Ann Oncol 32:1475&#x02013;1495. 10.1016/j.annonc.2021.09.019<pub-id pub-id-type="pmid">34678411</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name><surname>Garcia-Saenz</surname><given-names>JA</given-names></name><name><surname>Blancas</surname><given-names>I</given-names></name><name><surname>Echavarria</surname><given-names>I</given-names></name><etal/></person-group><article-title>SEOM-GEICAM-SOLTI clinical guidelines in advanced breast cancer (2022)</article-title><source>Clin Transl Oncol</source><year>2023</year><volume>25</volume><fpage>2665</fpage><lpage>2678</lpage><pub-id pub-id-type="doi">10.1007/s12094-023-03203-8</pub-id><pub-id pub-id-type="pmid">37148499</pub-id>
</element-citation><mixed-citation id="mc-CR22" publication-type="journal">Garcia-Saenz JA, Blancas I, Echavarria I et al (2023) SEOM-GEICAM-SOLTI clinical guidelines in advanced breast cancer (2022). Clin Transl Oncol 25:2665&#x02013;2678. 10.1007/s12094-023-03203-8<pub-id pub-id-type="pmid">37148499</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name><surname>Thill</surname><given-names>M</given-names></name><name><surname>L&#x000fc;ftner</surname><given-names>D</given-names></name><name><surname>Kolberg-Liedtke</surname><given-names>C</given-names></name><etal/></person-group><article-title>AGO recommendations for the diagnosis and treatment of patients with locally advanced and metastatic breast cancer: update 2022</article-title><source>Breast Care (Basel)</source><year>2022</year><volume>17</volume><fpage>421</fpage><lpage>429</lpage><pub-id pub-id-type="doi">10.1159/000524789</pub-id><pub-id pub-id-type="pmid">36156913</pub-id>
</element-citation><mixed-citation id="mc-CR23" publication-type="journal">Thill M, L&#x000fc;ftner D, Kolberg-Liedtke C et al (2022) AGO recommendations for the diagnosis and treatment of patients with locally advanced and metastatic breast cancer: update 2022. Breast Care (Basel) 17:421&#x02013;429. 10.1159/000524789<pub-id pub-id-type="pmid">36156913</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><mixed-citation publication-type="other">Associazione Italiana Oncologia Media (AIOM) (2023) [Advanced Breast Cancer Guideline]</mixed-citation></ref><ref id="CR25"><label>25.</label><mixed-citation publication-type="other">National Institute for Health and Care Excellence (NICE) (2023) Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments (TA862)</mixed-citation></ref><ref id="CR26"><label>26.</label><mixed-citation publication-type="other">National Institute for Health and Care Excellence (NICE) (2002) Guidance on the use of trastuzumab for the treatment of advanced breast cancer (TA34)</mixed-citation></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name><surname>Swain</surname><given-names>SM</given-names></name><name><surname>Baselga</surname><given-names>J</given-names></name><name><surname>Kim</surname><given-names>S-B</given-names></name><etal/></person-group><article-title>Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer</article-title><source>N Engl J Med</source><year>2015</year><volume>372</volume><fpage>724</fpage><lpage>734</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1413513</pub-id><pub-id pub-id-type="pmid">25693012</pub-id>
</element-citation><mixed-citation id="mc-CR27" publication-type="journal">Swain SM, Baselga J, Kim S-B et al (2015) Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med 372:724&#x02013;734. 10.1056/NEJMoa1413513<pub-id pub-id-type="pmid">25693012</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name><surname>Hartkopf</surname><given-names>AD</given-names></name><name><surname>Walter</surname><given-names>CB</given-names></name><name><surname>Kolberg</surname><given-names>H-C</given-names></name><etal/></person-group><article-title>Attrition in the first three therapy lines in patients with advanced breast cancer in the German real-world PRAEGNANT registry</article-title><source>Geburtshilfe Frauenheilkd</source><year>2024</year><volume>84</volume><fpage>459</fpage><lpage>469</lpage><pub-id pub-id-type="doi">10.1055/a-2286-5372</pub-id><pub-id pub-id-type="pmid">38817595</pub-id>
</element-citation><mixed-citation id="mc-CR28" publication-type="journal">Hartkopf AD, Walter CB, Kolberg H-C et al (2024) Attrition in the first three therapy lines in patients with advanced breast cancer in the German real-world PRAEGNANT registry. Geburtshilfe Frauenheilkd 84:459&#x02013;469. 10.1055/a-2286-5372<pub-id pub-id-type="pmid">38817595</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name><surname>Colomer</surname><given-names>R</given-names></name><name><surname>Hall</surname><given-names>P</given-names></name><name><surname>Szkultecka-Debek</surname><given-names>M</given-names></name><etal/></person-group><article-title>Real-world treatment in patients with HER2+ metastatic breast cancer</article-title><source>Breast Cancer Res Treat</source><year>2018</year><volume>168</volume><fpage>197</fpage><lpage>205</lpage><pub-id pub-id-type="doi">10.1007/s10549-017-4567-z</pub-id><pub-id pub-id-type="pmid">29170976</pub-id>
</element-citation><mixed-citation id="mc-CR29" publication-type="journal">Colomer R, Hall P, Szkultecka-Debek M et al (2018) Real-world treatment in patients with HER2+ metastatic breast cancer. Breast Cancer Res Treat 168:197&#x02013;205. 10.1007/s10549-017-4567-z<pub-id pub-id-type="pmid">29170976</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name><surname>Tripathy</surname><given-names>D</given-names></name><name><surname>Brufsky</surname><given-names>A</given-names></name><name><surname>Cobleigh</surname><given-names>M</given-names></name><etal/></person-group><article-title>De novo versus recurrent HER2-positive metastatic breast cancer: patient characteristics, treatment, and survival from the SystHERs registry</article-title><source>Oncologist</source><year>2020</year><volume>25</volume><fpage>e214</fpage><lpage>e222</lpage><pub-id pub-id-type="doi">10.1634/theoncologist.2019-0446</pub-id><pub-id pub-id-type="pmid">32043771</pub-id>
</element-citation><mixed-citation id="mc-CR30" publication-type="journal">Tripathy D, Brufsky A, Cobleigh M et al (2020) De novo versus recurrent HER2-positive metastatic breast cancer: patient characteristics, treatment, and survival from the SystHERs registry. Oncologist 25:e214&#x02013;e222. 10.1634/theoncologist.2019-0446<pub-id pub-id-type="pmid">32043771</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name><surname>Varghese</surname><given-names>D</given-names></name><name><surname>Cruz</surname><given-names>GI</given-names></name><name><surname>Johanson</surname><given-names>C</given-names></name><etal/></person-group><article-title>A real-world study of treatment sequences and second-line clinical outcomes in patients with HER2-positive metastatic breast cancer in US community practice</article-title><source>Int J Clin Oncol</source><year>2024</year><volume>29</volume><fpage>780</fpage><lpage>789</lpage><pub-id pub-id-type="doi">10.1007/s10147-024-02492-5</pub-id><pub-id pub-id-type="pmid">38528295</pub-id>
</element-citation><mixed-citation id="mc-CR31" publication-type="journal">Varghese D, Cruz GI, Johanson C et al (2024) A real-world study of treatment sequences and second-line clinical outcomes in patients with HER2-positive metastatic breast cancer in US community practice. Int J Clin Oncol 29:780&#x02013;789. 10.1007/s10147-024-02492-5<pub-id pub-id-type="pmid">38528295</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name><surname>Cheng</surname><given-names>H-F</given-names></name><name><surname>Tsai</surname><given-names>Y-F</given-names></name><name><surname>Huang</surname><given-names>C-C</given-names></name><etal/></person-group><article-title>Clinical outcomes and metastatic behavior between de novo versus recurrent HER2-positive metastatic breast cancer: a 17-year single-institution cohort study at Taipei Veterans General Hospital</article-title><source>J Chin Med Assoc</source><year>2022</year><volume>85</volume><fpage>88</fpage><lpage>94</lpage><pub-id pub-id-type="doi">10.1097/JCMA.0000000000000622</pub-id><pub-id pub-id-type="pmid">34561409</pub-id>
</element-citation><mixed-citation id="mc-CR32" publication-type="journal">Cheng H-F, Tsai Y-F, Huang C-C et al (2022) Clinical outcomes and metastatic behavior between de novo versus recurrent HER2-positive metastatic breast cancer: a 17-year single-institution cohort study at Taipei Veterans General Hospital. J Chin Med Assoc 85:88&#x02013;94. 10.1097/JCMA.0000000000000622<pub-id pub-id-type="pmid">34561409</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name><surname>Grinda</surname><given-names>T</given-names></name><name><surname>Antoine</surname><given-names>A</given-names></name><name><surname>Jacot</surname><given-names>W</given-names></name><etal/></person-group><article-title>Evolution of overall survival and receipt of new therapies by subtype among 20 446 metastatic breast cancer patients in the 2008&#x02013;2017 ESME cohort</article-title><source>ESMO Open</source><year>2021</year><volume>6</volume><fpage>100114</fpage><pub-id pub-id-type="doi">10.1016/j.esmoop.2021.100114</pub-id><pub-id pub-id-type="pmid">33895695</pub-id>
</element-citation><mixed-citation id="mc-CR33" publication-type="journal">Grinda T, Antoine A, Jacot W et al (2021) Evolution of overall survival and receipt of new therapies by subtype among 20 446 metastatic breast cancer patients in the 2008&#x02013;2017 ESME cohort. ESMO Open 6:100114. 10.1016/j.esmoop.2021.100114<pub-id pub-id-type="pmid">33895695</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><mixed-citation publication-type="other">European Medicines Agency (EMA) (2021) TUKYSA: summary of product characteristics. <ext-link ext-link-type="uri" xlink:href="https://www.ema.europa.eu/en/documents/product-information/tukysa-epar-product-information_en.pdf">https://www.ema.europa.eu/en/documents/product-information/tukysa-epar-product-information_en.pdf</ext-link>. Accessed 19 Aug 2022</mixed-citation></ref><ref id="CR35"><label>35.</label><mixed-citation publication-type="other">European Medicines Agency (EMA) ENHERTU | EUROPEAN MEDICINES AGENCY (EMA). <ext-link ext-link-type="uri" xlink:href="https://www.ema.europa.eu/en/medicines/human/EPAR/enhertu">https://www.ema.europa.eu/en/medicines/human/EPAR/enhertu</ext-link>. Accessed 25 Jul 2024</mixed-citation></ref><ref id="CR36"><label>36.</label><mixed-citation publication-type="other">European Medicines Agency (EMA) (2022) Summary of opinion (post authorisation): ENHERTU &#x000ae;. <ext-link ext-link-type="uri" xlink:href="https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-enhertu-ii-14_en.pdf">https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-enhertu-ii-14_en.pdf</ext-link>. Accessed 19 Aug 2024</mixed-citation></ref><ref id="CR37"><label>37.</label><citation-alternatives><element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name><surname>Geurts</surname><given-names>SME</given-names></name><name><surname>Ibragimova</surname><given-names>KIE</given-names></name><name><surname>Ding</surname><given-names>N</given-names></name><etal/></person-group><article-title>Time trends in real-world treatment patterns and survival in patients diagnosed with de novo HER2+ metastatic breast cancer: an analysis of the SONABRE registry</article-title><source>Breast Cancer Res Treat</source><year>2024</year><volume>205</volume><fpage>287</fpage><lpage>302</lpage><pub-id pub-id-type="doi">10.1007/s10549-023-07235-0</pub-id><pub-id pub-id-type="pmid">38381274</pub-id>
</element-citation><mixed-citation id="mc-CR37" publication-type="journal">Geurts SME, Ibragimova KIE, Ding N et al (2024) Time trends in real-world treatment patterns and survival in patients diagnosed with de novo HER2+ metastatic breast cancer: an analysis of the SONABRE registry. Breast Cancer Res Treat 205:287&#x02013;302. 10.1007/s10549-023-07235-0<pub-id pub-id-type="pmid">38381274</pub-id>
</mixed-citation></citation-alternatives></ref></ref-list></back></article>